This study focuses on gastric cancer, which is cancer in the stomach. Researchers want to learn how the tumor microenvironment (TME), or the area around a tumor, changes before and after treatment using a mix of immunotherapy and chemotherapy. Immunotherapy helps the immune system fight cancer, while chemotherapy uses medicine to kill cancer cells. They hope to find out why some patients respond better to these treatments than others.
- Participants must be between 18 and 70 years old and not bedridden.
- Must have advanced gastric cancer and ready for treatment with specific drugs: S-1, oxaliplatin, and either nivolumab or sintilimab.
- Those with recent history of other cancers or previous treatments like chemotherapy are not eligible.
How understandable was the trial content above?
Hard to understand
Easy to understand